Spenser Lin No Comments

Healthcare News, Deals, and Investments Update May 18th, 2026

LECO_Weekly-Healthcare-News_5-18-2026-1Download
  1. Boston Scientific Announces $1.5 billion Strategic Investment in MiRus LLC Boston Scientific Corporation (NYSE: BSX) announced a $1.5 billion strategic investment for an approximately 34% equity stake in MiRus LLC, a privately held company developing proprietary biomaterials, implants, and procedural solutions for cardiovascular and orthopedic diseases. Announced May 18, 2026, the agreement includes an exclusive option to acquire MiRus’ SIEGEL™ Balloon Expandable TAVR system, with potential additional payments of up to $3 billion upon clinical and regulatory milestones. The nickel-free, rhenium-alloy valve features a smaller delivery sheath, precise placement, and promising early clinical results in the ongoing STAR pivotal trial. The investment strengthens Boston Scientific’s interventional cardiology portfolio in the rapidly growing aortic stenosis market. (Link)
  2. J.P. Morgan, KKR, BofA Securities, and Barclays led the $478.7 million initial public offering of GMR Solutions (NYSE: GMRS) at a revised price of $15 per share GMR Solutions (NYSE: GMRS), the largest provider of emergency medical services in the U.S., priced its IPO at $15 per share, raising $478.7 million. The offering was led by a major syndicate including J.P. Morgan and KKR, with the latter also providing a $500 million concurrent private placement to bolster the company’s balance sheet. GMR Solutions plans to use the IPO proceeds primarily to pay down its existing debt. Despite the offering price being lowered from initial expectations, the IPO values the company at approximately $3.4 billion. The deal highlights significant institutional interest in the stabilization and growth potential of essential emergency and transport healthcare services. (Link)
  3. Prestige Consumer Healthcare (NYSE:PBH) Announces Acquisition of LaCorium Health Prestige Consumer Healthcare Inc. has entered into a definitive agreement to acquire LaCorium Health, a leading Australian platform in therapeutic skin care, lip, foot, and skin treatments. Announced May 13–14, 2026 alongside fiscal results, the approximately $150 million cash deal adds a high-growth, asset-light international OTC portfolio with strong market positions and expected double-digit revenue growth. The acquisition enhances Prestige’s dermatological offerings and geographic diversification. (Link)
  4. Lumexa Imaging (NASD: LMRI) executed its growth strategy by adding four new centers through joint ventures with University of Pittsburgh Medical Center (UPMC) and Advocate Health Lumexa Imaging the addition of four new locations in 2026, advancing its strategy to expand in high-growth markets via strategic partnerships. The expansion includes entry into the Pennsylvania market through a joint venture with the University of Pittsburgh Medical Center (UPMC) and further growth in the Southeast with Advocate Health. These additions, consisting of two acquisitions and two de novo centers, bring Lumexa’s total to over 190 outpatient imaging centers. The company leverages these joint ventures for capital efficiency and repeatability, focusing on the sustained shift toward outpatient, lower-cost sites of care driven by an aging population. (Link)
  5. Coastal Medical Transportation Systems Acquires Alert Ambulance to Expand New England Regional Care Network Coastal Medical Transportation Systems (CMTS), a leading privately owned medical transportation provider in New England, has completed the acquisition of Alert Ambulance Service. Announced May 18, 2026, the deal further strengthens CMTS’s position as one of the largest and most comprehensive ambulance and medical transportation providers in the region, following its prior integration of Fallon and Lifeline Ambulance Services. The acquisition expands geographic coverage across Massachusetts, New Hampshire, and Rhode Island, increases fleet size to over 325 vehicles, and grows the combined workforce to nearly 1,500 clinicians and support staff. (Link)
  6. Wellgistics Health (NASD: WGRX) Accelerates Digital Health Expansion with Planned Acquisition of WellCare Today Wellgistics Health, Inc. announced a non-binding letter of intent to acquire WellCare Today, a remote monitoring company specializing in RPM, RTM, and CCM programs powered by Samsung Galaxy Watch technology. Announced May 14, 2026, the proposed ~$15 million transaction (including $3 million cash and performance-based earnout in preferred stock) will integrate WellCare Today’s HealthAssist® platform with Wellgistics’ MSO pilot through Kare Clinicals and its network of over 6,500 independent pharmacies. The combination aims to enhance patient engagement, medication adherence, chronic care management, and reimbursement opportunities through wearable-enabled remote monitoring. (Link)
  7. Lorient Capital entered a strategic growth partnership with PeterMD to accelerate the national expansion of its proactive Medicine 3.0 healthcare platform Lorient Capital, a private equity firm exclusively focused on healthcare, has made a strategic investment in PeterMD to scale its personalized “Medicine 3.0” platform. PeterMD specializes in precision medicine, offering customized hormone health, longevity, and sexual wellness treatments through advanced diagnostics and proactive care. Lorient Capital is deploying capital from its $500 million Healthcare Fund III to fuel PeterMD’s national growth, aiming to transform the traditional reactive healthcare model. The partnership focuses on enhancing clinical outcomes and operational efficiency as PeterMD seeks to expand its footprint and bring precision-based integrated medicine to a broader national patient base. (Link)
  8. Blackstone and KKR & Co. Inc. reached a restructuring deal to take over the dental firm Affordable Care after slashing its total debt by 70% Direct lenders Blackstone and KKR are set to take control of Affordable Care, one of the largest U.S. dental services providers, following a major debt restructuring. The deal involves the lenders in a $1.4 billion private credit structure swapping their debt for equity, effectively slashing the dental firm’s debt load by approximately 70%. This restructuring provides Affordable Care with a significantly improved balance sheet to manage its extensive network of dental practices. The move underscores the increasing trend of major private credit lenders like Blackstone and KKR transitioning from creditors to equity owners to stabilize and preserve value in distressed healthcare portfolios. (Link)
  9. Quince Therapeutics (NASDAQ: QNCX)  Acquires Orphai Therapeutics and Raises up to $187 Million in Private Placement to Advance Pulmonary Pipeline Quince Therapeutics, Inc. announced the acquisition of Orphai Therapeutics, bringing in LAM-001, an inhaled formulation of rapamycin (sirolimus) for rare pulmonary diseases including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome (BOS). Concurrently, Quince entered a private placement to raise up to $187 million ($115 million upfront + up to $72 million from warrants), led by Balyasny Asset Management with participation from a strong syndicate of healthcare investors. The combined proceeds are expected to fund operations through the end of 2028 and support multiple clinical milestones, including Phase 2 data readouts in 2027 and 2028.
  10. Orthopaedic Specialty Group and OrthoConnecticut Merge to Create Statewide Physician-Led Platform Powered by HOPCo Technology Partnership Orthopaedic Specialty Group (OSG) and OrthoConnecticut have officially merged, creating a dominant, physician-led musculoskeletal (MSK) care platform across Connecticut. The merger is bolstered by a strategic partnership with Healthcare Outcomes Performance Company (HOPCo), the global leader in MSK value-based care. While the organizations merge their clinical networks to improve patient access, HOPCo provides the digital infrastructure, including advanced analytics and care management tools, to optimize outcomes and reduce total care costs. This collaboration allows the unified practice to scale thoughtfully while preserving clinical autonomy and delivering high-quality orthopedic services closer to home for patients throughout the Connecticut. (Link)
  11. Sweetser merged with Common Ties Mental Health Services to create Maine’s largest provider of Certified Community Behavioral Health Clinic services Common Ties Mental Health Services, based in Lewiston, has officially merged with Sweetser to create a robust behavioral health network in Maine. This merger establishes Sweetser as the state’s largest provider of Certified Community Behavioral Health Clinic (CCBHC) services, integrating Common Ties’ regional expertise into Sweetser’s broad statewide platform. The investment focuses on streamlining mental health delivery, expanding free community training, and increasing access to specialized behavioral health services. By consolidating resources, the combined entity aims to build a more sustainable and accessible care model to address the rising mental health needs across Maine’s diverse and often underserved communities. (Link)
  12. Gryphon Investors-backed LEARN Behavioral acquired Little Leaves Behavioral Services from FullBloom, a portfolio company of American Securities LEARN Behavioral, a leading autism therapy provider backed by Gryphon Investors, has acquired Little Leaves Behavioral Services from FullBloom. FullBloom is a portfolio company of American Securities and sold the division to refocus on its core educational services. Little Leaves operates 18 early-intervention centers across Maryland, Virginia, and Florida, which will now join LEARN’s extensive national network. This acquisition allows LEARN Behavioral to expand its density in the Mid-Atlantic and establish a larger presence in the Florida market. The deal represents a significant consolidation within the ABA (Applied Behavior Analysis) sector, focusing on scaling early-intervention services for children with autism. (Link)
  13. Arcadea Group expanded its mission-critical software presence in Brazil through the acquisition of hemotherapy and hospital software provider Sofis Arcadea Group, a long-term investor in high-quality software firms, has acquired Sofis, a Rio de Janeiro-based provider of healthcare software. Sofis specializes in mission-critical solutions for blood bank management (hemotherapy) and hospital ERP systems, serving over 300 institutions across Brazil. This acquisition marks Arcadea’s fourth investment in the Brazilian healthcare technology market. Arcadea plans to leverage its permanent capital base to support Sofis’ long-term product development and international expansion. By transitioning from a founder-owned model to one backed by Arcadea’s global resources, Sofis aims to modernize its platform and deepen its penetration into the complex Latin American healthcare technology landscape. (Link)
  14. Iterative Health Acquires Cardiology Research Sites from NextStage Clinical Research Iterative Health, a healthcare technology and services company focused on accelerating clinical research, has acquired three cardiology research sites from NextStage Clinical Research in Texas (Beaumont, Port Arthur, and Waco). Announced on May 14, 2026, with Bourne Partners serving as financial advisor, the deal expands Iterative Health’s elite site network and strengthens its capabilities in cardiovascular research — a therapeutic area affecting nearly half of U.S. adults. The sites bring experienced teams, strong community provider connections, and an active trial portfolio, enhancing patient access to innovative therapies while providing sponsors with high-performing, real-world research centers. (Link)
  15. HealthScape Advisors Acquires PayerAlly to Strengthen Pharmacy Benefit Management Capabilities HealthScape Advisors, a leading payer advisory firm and a Chartis company, has acquired PayerAlly, an independent pharmacy consulting firm specializing in pharmacy benefit management (PBM) strategy, procurement, and optimization. Announced May 12, 2026 (with coverage extending through mid-May), the deal enhances HealthScape’s ability to help health plans and employers address rapidly rising prescription drug costs through integrated, clinically informed total cost-of-care solutions. PayerAlly’s expertise in PBM strategy complements HealthScape’s broader payer advisory platform, supporting more effective management of one of healthcare’s fastest-growing expense categories. (Link)
  16. NeuroVision Acquires Durin Life Sciences to Advance Neurodegenerative Diagnostics NeuroVision, a diagnostics company developing early detection tools for Alzheimer’s and other neurodegenerative diseases, has acquired Durin Life Sciences, a fellow diagnostics developer. Announced May 15, 2026, the deal adds Durin’s blood-based Duritect™ tests for early detection and monitoring of Alzheimer’s, Parkinson’s, and ALS. The combination accelerates NeuroVision’s platform for earlier, more accessible diagnosis and disease management, addressing critical gaps in neurodegenerative care. (Link)
  17. IKS Health Acquires ARAI Solutions to Accelerate Agentic AI Capabilities IKS Health, a global leader in care enablement and AI-driven clinical solutions, has acquired ARAI Solutions, a specialized AI management and technology company focused on biomedical knowledge graphs and clinical reasoning infrastructure. Announced May 13–14, 2026, the deal enhances IKS Health’s ability to build proprietary small language models and agentic AI systems for clinical, operational, and revenue cycle workflows. ARAI’s ontology layer and applied research expertise will improve the reliability, auditability, and efficiency of IKS’s AI platforms serving health systems nationwide. (Link)
  18. Signant Health Acquires Ametris to Create End-to-End eCOA and Digital Outcome Measures Platform Signant Health, a leading evidence generation company for clinical trials, has acquired Ametris (formerly ActiGraph), a global digital health solutions provider specializing in wearable-derived clinical outcome measures. The deal integrates Signant’s eCOA (electronic Clinical Outcome Assessment) solutions with Ametris’ validated sensor-based technologies for objective measurement of physical activity and function. The combined platform will deliver multimodal evidence—patient-reported outcomes alongside continuous real-world data—simplifying complex trials, accelerating insights, and strengthening regulatory submissions, particularly in CNS and other therapeutic areas. (Link)
  19. iSpecimen Inc. (NASD: ISPC) Secures $2.5 Million Private Placement to Support Operations Amid 89% Annual Stock Decline iSpecimen Inc. finalized a $2.5 million private placement on May 11, 2026, to bolster working capital. The biospecimen marketplace provider, currently valued at $3.39 million, has seen its share price plummet 89% over the past year to $4.57. This funding follows a $5.5 million raise in late 2025, aimed at mitigating rapid cash burn. iSpecimen, which connects medical researchers with specimen providers, will use the proceeds for general corporate purposes as it navigates significant financial challenges and seeks to stabilize its market position. (Link)
  20. Blue Sea Capital supported One Physics in its strategic acquisition and partnership with Petrone Associates to expand its Northeast clinical services footprint One Physics, the largest outsourced medical physics services company in North America, has announced its 22nd acquisition with the addition of New York-based Petrone Associates. This strategic move, backed by growth-oriented private equity firm Blue Sea Capital, significantly strengthens One Physics’ presence in the New York City metropolitan market and Northern New Jersey. The partnership leverages One Physics’ national scale and Petrone’s established clinical reputation to provide comprehensive diagnostic and therapy medical physics, radiation safety, and dosimetry services. Blue Sea Capital, managing over $1.5 billion in assets, remains committed to accelerating One Physics’ industry leadership through continued regional consolidation. (Link)

Venture Deals and Other

  1. Sound Ventures, Alumni Ventures, Link Ventures, Redesign Health, and RRE Ventures invested $17 million in Anomaly Insights to address healthcare payer-provider information asymmetry. Anomaly Insights, an AI-powered payer intelligence firm, secured $17 million in funding led by Sound Ventures to combat the informational gap between healthcare payers and providers. The investment includes participation from RRE Ventures and Redesign Health, focusing on Anomaly’s real-time AI platform that identifies and corrects billing errors and payment inaccuracies. The company aims to reduce the massive administrative waste in the U.S. healthcare system by providing transparency in the claims process. This new capital will be used to enhance Anomaly’s machine learning models and scale its solutions across larger health systems and insurance networks to streamline payment cycles. (Link)
  2. McKesson Ventures, FCA Venture Partners, Sanofi Ventures, and AIX Ventures led a $26 million Series A for Branchlab to scale its AI-driven biopharma commercialization platform Branchlab raised $26 million in a Series A round led by McKesson Ventures to accelerate the growth of its Pathwai™ platform. The round, which included corporate venture backing from Sanofi Ventures, brings Branchlab’s total funding to $35 million. The company uses privacy-first AI to optimize the patient journey and enhance pharmaceutical commercialization, reporting a 70% increase in patient activation efficiency. Branchlab intends to use the capital to expand its engineering and data science teams in New York and Colorado. By providing real-time insights to biopharma brands, Branchlab aims to make pharmaceutical marketing more effective and patient-centric through advanced data analytics. (Link)
  3. AIX Ventures led a $2 million pre-Seed funding round for Chromie Health to develop its autonomous AI-powered hospital workforce management platform Chromie Health, a New York-based startup, secured $2 million in pre-Seed funding led by AIX Ventures to tackle the hospital staffing crisis. The company develops autonomous AI agents that automate complex administrative tasks and workforce scheduling without requiring deep IT integration. Chromie Health’s platform is designed to alleviate the burnout of clinical staff by handling the logistics of hospital operations through intelligent automation. The investment will support the development of additional “digital agents” capable of reasoning through clinical context and staffing needs. This seed capital positions Chromie Health to pilot its solutions across more health systems seeking to modernize their operational efficiency. (Link)
  4. Blueprint Equity, Villain Capital, Z21 Ventures, and Bienville Capital led a $14 million growth funding round for pediatric-focused AI operating system Develo Develo, an AI-native operating system for pediatric practices, raised $14 million in a funding round led by Blueprint Equity. The platform integrates clinical workflows, billing, and parent engagement into a single AI-driven ecosystem, currently serving hundreds of providers across 25 states. The capital will be used to accelerate the development of specialized AI tools, including automated charge capture and AI-assisted scribing for pediatricians. Develo aims to reduce the administrative burden that leads to physician burnout while improving the financial performance of independent pediatric practices. The investment highlights a growing trend toward specialty-specific AI platforms that address unique clinical and operational workflows. (Link)
  5. Thrive Capital, General Catalyst, Accel, Bain Capital Ventures, Redpoint, BoxGroup, and Pear VC backed Forus with $160 million to build its AI-powered pharmaceutical delivery network Forus, formerly known as Tandem, raised $160 million in a major funding round backed by top-tier venture firms including Thrive Capital and General Catalyst. The company is building an AI-powered infrastructure that connects doctors, pharmacies, and biopharma companies to streamline the drug fulfillment process. Forus automates the “last-mile” clinical steps, such as insurance authorizations, to ensure patients receive treatments faster. With five of the top ten global biopharma companies already utilizing the network, Forus plans to use the investment to expand its nationwide reach and further integrate its AI layer into existing physician and pharmacy workflows to eliminate treatment delays. (Link)
  6. Uncork Capital, Frist Cressey Ventures, Moxxie Ventures, and Coalition Operators provided $11.6 million in Seed funding for the launch of Knit Health’s clinical behavior AI Knit Health, a spin-out from UC Berkeley, launched with $11.6 million in Seed funding co-led by Uncork Capital and Frist Cressey Ventures. The company is developing a Large Clinical Behavior Model (LCBM) trained on real-world clinician decisions across 30 U.S. health systems. Knit Health’s AI agents are designed to handle triage, patient flow, and care coordination by learning from collective clinical experience rather than just static text. The funding will be used to scale its foundational intelligence layer and deploy AI agents that assist in high-stakes hospital environments. This investment reflects a shift toward “Action AI” that can reason and perform complex tasks in clinical settings. (Link)
  7. Salesforce Ventures, Echo Health Ventures, Susa Ventures, Matrix Partners, and HC9 Ventures raised $17.5 million in Series A funding for Optura’s AI governance platform Optura, a Nashville-based healthcare AI governance platform, secured $17.5 million in Series A funding led by Salesforce Ventures. The investment, which brings Optura’s total funding to $25 million, will support the expansion of its “Return on AI Investment” (ROAI) platform. Optura helps enterprise healthcare organizations, such as Independence Blue Cross, map fragmented data and measure the efficacy of their AI agents. The capital will be used to scale partnerships with LLM providers and grow its engineering teams. By providing a unified knowledge layer, Optura enables healthcare leaders to prioritize AI use cases based on actual operational readiness and projected business value. (Link)
  8. Norwest, Primary, Next Ventures, Constellation, and Scrub Capital led a $25 million financing round for Tokaido Health to launch its AI medication steerage platform. Tokaido Health emerged from stealth with $25 million in funding led by Norwest and Primary to address skyrocketing pharmacy costs for employers. The platform utilizes AI and behavioral economics to identify same-or-better medications that cost less, steering members toward high-value options like biosimilars. Tokaido layers on top of existing PBM stacks, allowing for a seamless integration without plan redesigns. The investment will be used to scale its concierge-style member outreach and expand its clinical reasoning engine. By focusing on site-of-care steerage and polypharmacy reconciliation, Tokaido aims to eliminate billions in wasted drug spending while improving the patient experience. (Link)
  9. Andera Partners, American Century Investments, Clarevia Ventures, Time BioVentures, View Ventures, Cadence Healthcare Ventures, and Anduril Investors led a $20 million Series D for Rivermark Medical Rivermark Medical, a urology-focused medical device company, raised $20 million in Series D funding led by Andera Partners. The financing will support the ongoing RAPID III pivotal clinical trial for the FloStent™ System, a non-surgical treatment for men with benign prostatic hyperplasia (BPH). The investment syndicate includes American Century Investments and Time BioVentures, focusing on bringing this reversible, office-based therapy to market. The FloStent is designed to be easily adjustable and tissue-preserving, offering a first-line alternative to more invasive surgical procedures. The capital will also be used to prepare for a U.S. commercial launch following expected regulatory approval. (Link)
  10. Aulis Capital led a $13.4 million Seed funding round for Shyld AI to accelerate the deployment of its autonomous AI-driven infection control solutions Shyld AI, a healthcare technology company, secured $13.4 million in Seed funding led by Aulis Capital to expand its active intelligence solutions for hospital facilities. Shyld AI develops autonomous physical agents that use AI and UV disinfection to reduce environmental contamination in high-risk areas like operating rooms. The funding will accelerate deployments across U.S. health systems and support the company’s expansion into regulated pharmaceutical manufacturing environments. By streamlining infection control and compliance without adding to the workload of hospital staff, Shyld AI aims to improve patient safety and operational efficiency. The investment marks a significant milestone in the adoption of autonomous hygiene agents in healthcare. (Link)

Sign up for all the Lawrence, Evans & Co., LLC news and activities
CLICK HERE

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update May 11th, 2026

LECO_Weekly-Healthcare-News_5-11-2026Download
  1. Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease Angelini Pharma S.p.A., an international pharmaceutical company and part of Italy’s Angelini Industries Group, entered into a definitive agreement to acquire Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), a Coral Gables, FL-based commercial-stage biopharmaceutical company focused on rare and difficult-to-treat diseases, in an all-cash transaction valued at approximately $4.1 billion or $31.50 per share. The deal, announced May 7, 2026, represents a premium to Catalyst’s recent trading prices and will expand Angelini Pharma’s U.S. market presence and rare-disease portfolio, particularly in brain health and neurological conditions. Closing is expected in the third quarter of 2026, subject to Catalyst stockholder approval, regulatory clearances, and other customary conditions. (Link)
  2. Roche Holding AG (SIX: RO, ROP; OTCQX: RHHBY), the Swiss pharmaceutical and diagnostics giant, entered into a definitive merger agreement to acquire PathAI, a Boston-based AI-powered digital pathology company, for USD 750 million upfront plus up to USD 300 million in milestone payments, valuing the deal at up to USD 1.05 billion. Roche (SIX: RO, ROP; OTCQX: RHHBY) has signed a definitive merger agreement to acquire Boston-based digital pathology firm PathAI. Under the terms of the agreement, Roche will pay a purchase price of USD 750 million upfront and additional milestone payments of up to USD 300 million, bringing total potential consideration to USD 1.05 billion. Roche has partnered with the company since 2021, expanding their agreement in 2024 to include the development of AI-enabled companion diagnostic algorithms. Roche Diagnostics will absorb PathAI as an operating unit after closing expected in H2 2026, pending regulatory clearance, accelerating Roche’s AI-powered diagnostics capabilities. (Link)
  3. Cross Country Healthcare, Inc. (NASD: CCRN), a Boca Raton-based technology-driven healthcare workforce solutions company, entered into a definitive agreement to be acquired by growth-oriented private equity firm Knox Lane in an all-cash transaction valued at approximately $437 million, or $13.25 per share. Cross Country Healthcare (NASDAQ: CCRN) has signed a definitive agreement to be taken private by Knox Lane, a growth-oriented investment firm, in an all-cash transaction valued at $437 million, or $13.25 per share. The price represents a premium of approximately 31% to CCRN’s closing price on May 6, 2026, and a 45% premium to its 90-day volume-weighted average trading price. Knox Lane is a private equity firm with $3.5 billion in assets under management. Upon completion, Cross Country Healthcare will become a privately held platform company in Knox Lane’s portfolio and will cease trading on Nasdaq, with closing expected in Q3 2026.  (Link)
  4. Sanford Health, a Sioux Falls, South Dakota-based nonprofit rural health system, and North Memorial Health, a Twin Cities-based Minnesota nonprofit health system, signed a definitive agreement to combine into a single nonprofit organization, supported by a planned $600 million investment. Sanford Health and North Memorial Health have signed a definitive agreement to combine into a single nonprofit health system. The transaction includes a $600 million investment in Twin Cities services. Sanford’s most recent annual revenue was nearly $11.7 billion in 2025, which reflects its merger with Marshfield Clinic Health System in Wisconsin. Sanford Health President and CEO Bill Gassen will continue to serve as president and chief executive officer of the combined organization. The partnership is expected to close sometime this year, subject to completion of regulatory processes and other customary closing conditions. (Link)
  5. The University of Pittsburgh Medical Center (UPMC), a Pittsburgh-headquartered nonprofit health care provider and insurer, and CommonSpirit Health, one of the nation’s largest nonprofit Catholic healthcare organizations, signed a definitive agreement transferring ownership of Steubenville, Ohio-based Trinity Health System to UPMC. UPMC and CommonSpirit Health have signed a definitive agreement transferring ownership of Trinity Health System to UPMC. The transfer includes Trinity West, Trinity East, Trinity St. Clairsville Neighborhood Hospital, Trinity Twin City Medical Center, and associated clinics, to UPMC. The transaction is expected to be completed in Fall 2026, pending regulatory review and customary closing conditions. The deal will allow UPMC to expand into the Midwest from its foothold in the mid-Atlantic. Financial terms were not disclosed. The deal marks UPMC’s first expansion into Ohio while supporting CommonSpirit’s multiyear asset-divestiture turnaround strategy. (Link)
  6. agilon health, inc. (NYSE: AGL), an Austin, TX-based value-based care platform partnering with primary care physicians on Medicare Advantage, saw its stock surge after delivering Q1 2026 revenue of $1.42 billion and GAAP EPS of $1.80, prompting upgrades from Deutsche Bank and Jefferies. agilon health (NYSE: AGL) shares surged sharply following a Q1 2026 earnings beat. Revenue came in at $1.42 billion versus analyst estimates of $1.38 billion, EPS (GAAP) of $1.80 crushed the consensus of $0.83, and Adjusted EBITDA of $53.84 million beat estimates of $36.15 million by nearly 49%. Deutsche Bank upgraded agilon health’s stock rating to Buy from Hold, raising its price target to $49.00, while Jefferies also upgraded the stock to Buy. For the full year, the company raised its 2026 Adjusted EBITDA guidance to $10–$40 million, with new CEO Tim O’Rourke commencing leadership. (Link)
  7. Addus Enters Indiana With HomeCourt Acquisition, Lines Up Second Deal Addus HomeCare Corporation (NASDAQ: ADUS), a Frisco, Texas-based provider of home and community-based personal care services, acquired HomeCourt Home Care, a Fort Wayne, Indiana-based non-medical home care agency. Addus HomeCare has entered the Indiana market through the acquisition of HomeCourt Home Care. The deal adds approximately $9.8 million in annualized revenue and expands Addus’ footprint into the Midwest with a strong regional provider of in-home personal care and supportive services for elderly and disabled clients. The transaction closed on May 1, 2026 and marks Addus’ continued geographic expansion strategy in the home-care sector. Financial terms were not disclosed. (Link)
  8. HealthVerity, Inc., a Philadelphia-based leader in privacy-protected real-world data exchange and patient identity solutions, entered into a definitive agreement to acquire Symphony Health Solutions Corporation, a commercial healthcare data and analytics business formerly part of ICON plc (NASDAQ: ICLR). HealthVerity has announced the acquisition of Symphony Health to combine its clinical data depth with Symphony’s commercial insights, creating a unified, AI-ready platform for life sciences, payers, and government entities. The transaction, announced on May 5, 2026, is expected to close in May 2026 subject to customary closing conditions. Financial terms were not disclosed. (Link)
  9. Elsevier completes acquisition of Mytonomy and introduces comprehensive end to end patient engagement solutions for healthcare providers. Elsevier, a global leader in scientific publishing and health information solutions (part of RELX plc), completed the acquisition of Mytonomy, Inc., a Washington, D.C.-based provider of cloud-based video patient engagement and education platforms for hospitals and health systems. Elsevier has completed the acquisition of Mytonomy to integrate its clinical content libraries with Mytonomy’s video-first patient engagement platform, creating end-to-end solutions that improve adherence, reduce readmissions, and support value-based care across the care continuum. The deal, closed on May 5, 2026, combines Elsevier’s trusted evidence-based content with Mytonomy’s HIPAA-compliant, personalized video and interactive tools already deployed at more than 300 U.S. healthcare organizations. Financial terms were not disclosed. (Link)
  10. CQ Medical, the Avondale, Pennsylvania-based global leader in radiotherapy positioning solutions formed in 2022 through the combination of CIVCO Radiotherapy and Qfix, acquired .decimal, a Sanford, Florida-based precision manufacturer of patient-specific radiotherapy beam-shaping devices. CQ Medical has acquired .decimal to expand its patient-specific cancer treatment portfolio. CQ Medical was formed in 2022 through the combination of CIVCO Radiotherapy and Qfix, bringing together decades of expertise in essential radiation therapy positioning and immobilization solutions. Serving the radiotherapy clinical community for more than 40 years, .decimal is a trusted partner known for its rapid production of customized, patient-specific devices—typically manufactured and shipped within 1–2 days of order receipt. To date, the company has delivered over 500,000 patient-specific treatment devices, and actively serves more than 900 cancer centers across the United States. Financial terms were not disclosed. (Link)
  11. Med Tech Solutions (MTS), a Valencia, California-based managed healthcare IT services provider and portfolio company of Silversmith Capital Partners, acquired Avarion (formerly Huntzinger Management Group), a two-time Best in KLAS healthcare IT advisory firm, to span the full care continuum. Silversmith Capital Partners-backed Med Tech Solutions has acquired Avarion to strengthen its managed services platform. Med Tech Solutions, a provider of managed healthcare IT services and a portfolio company of Silversmith Capital Partners, acquired Avarion, a healthcare IT advisory firm serving hospitals, health systems and care networks. The combination unites MTS’ EHR managed services, application support, and technology infrastructure expertise with Avarion’s deep experience in healthcare IT advisory, consulting, and leadership services. Robert Kitts, Avarion’s CEO and founding partner, will report to Mona Abutaleb, CEO of MTS, and lead the company’s strategic advisory and staffing services. Financial terms were not disclosed. (Link)
  12. TimelyCare, a Fort Worth, TX-based virtual care provider for higher education serving nearly 500 campuses nationwide, acquired Alongside, a clinician-designed AI coaching platform trusted by more than 200 schools, to expand its student support model with continuous early-intervention AI coaching. TimelyCare has acquired Alongside, a clinician-designed AI coaching platform for students. Alongside combines evidence-based skill-building with proprietary safety models that detect risk and connect students to additional support when needed. Trusted by nearly 500 campuses across the U.S., TimelyCare combines URAC-accredited clinical standards with a measurement-based approach, while Alongside is trusted by more than 200 schools nationwide. The acquisition expands TimelyCare’s approach beyond traditional points of clinical need, positioning the company to engage a broader student population earlier and more consistently across the care continuum. Financial terms were not disclosed. (Link)
  13. Xpress Wellness, a Goldman Sachs-backed Oklahoma City-based provider of urgent care, virtual primary care, occupational medicine, behavioral health and post-acute services, acquired Midwest Counseling Services, a Wichita, Kansas-based mental health clinic founded in 2022 serving older adults in senior communities. Goldman Sachs-backed Xpress Wellness has acquired Wichita-based Midwest Counseling Services. Founded in 2022, Midwest Counseling Services provides mental health services to older adults living in senior communities through approaches including talk therapy and individual counseling. Xpress Wellness is an Oklahoma City-based provider of urgent care, virtual primary care, occupational medicine, behavioral health and post-acute services across rural and suburban communities. Lisa Harrison, founder of Midwest Counseling Services, now serves as Xpress Wellness’ Director of Operations of Post-Acute overseeing the Kansas market, with the deal expanding the acquirer’s behavioral health footprint in Kansas and adjacent states. (Link)
  14. Pediatrica Health Group, a Miami-based multi-site pediatric primary care platform backed by M33 Growth, acquired the long-established Westchester, Miami-Dade pediatric practice of Dr. Juan Ruiz-Unger to expand equitable access to care amid rising regional population growth. Pediatrica Health Group, backed by Boston-based venture and growth-stage investor M33 Growth, has acquired an additional pediatric practice in the Westchester neighborhood of Miami-Dade County. For over 40 years, Dr. Juan Ruiz-Unger has delivered compassionate, evidence-based care to Westchester families. Roberto Palenzuela, Chief Executive Officer of Pediatrica Health Group, said the acquisition aligns with the company’s goal of supporting physicians who want to expand access while maintaining continuity of care within their communities. Financial terms were not disclosed. The deal continues Pediatrica’s multi-site pediatric primary care roll-up strategy across South Florida. (Link)
  15. SpinLife, a Columbus, Ohio-based omni-channel mobility and home accessibility retailer owned by Brentwood, Tennessee-based Complex Rehab Technology leader Numotion, acquired Triton Medical and opened a new SpinLife retail store in Lady Lake, Florida, expanding its Central Florida footprint. Numotion-owned SpinLife has acquired Triton Medical and launched a new Central Florida retail location. SpinLife, owned by Numotion, said in a May 5 announcement that the acquisition was completed on April 22. The retail location is now operating as SpinLife — Lady Lake and strengthens the company’s presence in central Florida and enhancing service to the growing Lady Lake and The Villages communities. Matt Chesshire, Triton Medical’s founder, will remain at the Lady Lake store as general manager. Numotion acquired SpinLife in 2021. Financial terms were not disclosed. (Link)
  16. Care Advantage, Inc., a Mid-Atlantic-based privately held home care provider, announced the acquisition of First Priority Home Care, a Columbia, South Carolina-based non-medical home care agency, advancing its targeted expansion strategy across the Mid-Atlantic and Southeast. Care Advantage, Inc. has acquired Columbia, South Carolina-based First Priority Home Care. Care Advantage, one of the Mid-Atlantic’s largest privately held home care providers, today announced the acquisition of First Priority Home Care, based in Columbia, South Carolina. This latest transaction marks another step in Care Advantage’s continued expansion into the southern United States. First Priority Home Care is a non-medical home care agency based in Columbia, South Carolina, providing in-home support services to seniors and adults who need assistance. Financial terms of the deal were not disclosed. (Link)
  17. Standard Dental Labs Inc., (OTCQB:TUTH) an Orlando-based publicly traded dental laboratory consolidator, completed the acquisition of BRLIT Dental Laboratory, a Sarasota, Florida-based dental lab founded in 1977, adding approximately $886,000 in annual revenue. Standard Dental Labs Inc. (OTCQB: TUTH) has completed the acquisition of BRLIT Dental Laboratory in Sarasota, Florida. The transaction adds approximately $886,000 in annual revenue to Standard Dental Labs’ existing revenue base of approximately $236,000, bringing the company’s total annualized revenue to more than $1.1 million. The company holds a market capitalization of $6.54 million. BRLIT Dental Laboratory, founded in 1977, has served dentists throughout Florida for nearly five decades, and the acquisition expands the buyer’s footprint along Florida’s Gulf Coast. The company intends to continue pursuing strategic acquisitions in Florida’s dental laboratory industry. (Link)
  18. TopGum Industries Ltd. (TASE: TPGM), an Israel-based global leader in gummy-format dietary supplements, completed the acquisition of the U.S. gummy manufacturing operations of P&L Developments LLC, a Westbury, New York-based pharmaceutical and consumer healthcare CDMO, in a transaction valued at up to USD 35 million. TopGum Industries Ltd. (TASE: TPGM) has completed its acquisition of P&L Developments’ U.S. gummy manufacturing operations. The consideration, funded by TopGum’s existing resources, comprises US$10 million in cash at closing, 1,893,060 shares valued at approximately US$8 million at closing (based on a price of NIS 13 per share), and up to 4,022,751 additional shares (valued at up to US$17 million) as contingent consideration, payable upon achievement of agreed commercial and regulatory milestones.  (Link)
  19. Arete Health Announces Acquisitions of Virginia Rehabilitation & Wellness and Summerville Physical Therapy & Balance for Adults Arete Health, a physician-led multi-specialty practice management platform, acquired Virginia Rehabilitation & Wellness and Summerville Physical Therapy & Balance for Adults, two established physical therapy practices in Virginia. Arete Health has completed the acquisition of two Virginia-based physical therapy practices—Virginia Rehabilitation & Wellness and Summerville Physical Therapy & Balance for Adults—on May 5, 2026. The deals strengthen Arete’s outpatient rehabilitation footprint in the Mid-Atlantic and add specialized orthopedic, sports medicine, and balance therapy services. The combined practices serve several hundred patients weekly across multiple locations. Financial terms were not disclosed. (Link)

Venture Deals and Other

  1. Basata, a Phoenix-based AI company building the operational layer for U.S. healthcare, raised a $21 million Series A led by Basis Set Ventures with participation from Cowboy Ventures, PHX Ventures, Zenda Capital, and Victoria Treyger, bringing total funding to $24.5 million. Basata has closed a $21 million Series A funding round to scale its AI-driven healthcare administrative automation platform. The Series A was led by Basis Set Ventures, with participation from Cowboy Ventures, PHX Ventures, Zenda Capital, and Victoria Treyger. The round brings total funding to $24.5 million. Basis Set Ventures’ Lan Xuezhao led the round, joined by Cowboy Ventures’ Aileen Lee, PHX Ventures, Zenda Capital, and Victoria Treyger. The company has served more than 500,000 patients to date, including 100,000 patients during the past month alone, while working with specialty groups across cardiology, urology, gastroenterology, and ophthalmology. (Link)
  2. Dandelion Health, a New York-based clinical intelligence platform serving life sciences, raised a $14 million Series A led by Healthier Capital with participation from Colle Capital and existing investors Primary Venture Partners, Moxxie Ventures, and Convergent Ventures, to scale its multimodal clinical AI infrastructure. Dandelion Health has secured $14 million in Series A funding. Healthier Capital led the round, with participation from Colle Capital and existing investors Moxxie Ventures, Convergent Ventures and Primary Venture Partners. Built on a network spanning 73 hospitals and more than 15 million patients, Dandelion is unique in its ability to combine structured data — electronic medical records and claims — with unstructured clinical text and raw biological signals including ECG waveforms, echocardiogram videos, radiology imaging, pulmonary function tests, and ultrasound. The Series A financing will be used to expand Dandelion’s pharmaceutical partnerships, scale the company’s data and engineering infrastructure, and grow commercial and scientific teams. (Link)
  3. Enzo Health, a Lehi, Utah-based AI-driven platform for home health and post-acute care launched in 2024, raised a $20 million Series A led by global venture capital firm N47 with participation from existing investors Gradient (a Google-affiliated investment firm), Tandem Ventures, and Rigby Watts, bringing total funding to $26 million. Enzo Health has raised a $20 million Series A funding round. The round was led by N47, bringing the company’s total funding to $26M. Existing investors Gradient, Tandem Ventures, and Rigby Watts also participated. Existing investors Gradient (Palo Alto, a Google-affiliated investment firm), Tandem Ventures (Draper, UT), and Rigby Watts (Millcreek, UT) also participated. Launched in 2024, Enzo Health has grown revenue by more than 40X in twelve months and is now used by organizations that support over 500,000 patients annually. The funds will accelerate expansion into skilled nursing and hospice sectors. (Link)
  4. Travv, a Stillwater, Oklahoma-based AI-native diagnostic platform for veterinary medicine led by founder and CEO Derick Whitley, DVM, DACVP, closed a $1.6 million seed funding round led by Digitalis Ventures with participation from AniVC, to advance its cloud-based veterinary diagnostic platform. Travv has closed a $1.6 million seed funding round. Travv, a Stillwater, OK-based provider of an AI-native diagnostic platform for veterinary medicine, closed a $1.6m seed funding round. The round was led by Digitalis Ventures, with participation from AniVC. The funding will support continued development of Travv’s AI-native diagnostic platform for veterinary medicine, including product expansion, hospital onboarding, commercial growth, and key integrations. Digitalis Ventures backs founders solving critical problems in health. The firm invests in early-stage companies across life sciences, health technology & services, and animal health, while AniVC focuses on early-stage pet companies. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update May 4th, 2026

LECO_Weekly-Healthcare-News_5-4-2026Download
  1. UCB (ENX:UCB) to acquire clinical-stage biotech Candid Therapeutics for up to $2.2 billion to expand its immunology pipeline with novel T-cell engagers UCB has entered into a definitive agreement to acquire Candid Therapeutics for $2 billion in upfront payments and up to $200 million in potential development milestones. The transaction, which hijacks Candid’s planned reverse merger with Rallybio, brings a pipeline of T-cell engagers (TCEs) led by cizutamig (BCMAxCD3), a Phase 1/2-ready bispecific antibody demonstrating deep B-cell and plasma cell depletion with manageable safety in autoimmune patients. This deal positions UCB to compete directly in the emerging TCE autoimmune field alongside Gilead, accelerating its strategy in high-unmet-need immune-mediated diseases through off-the-shelf, outpatient-compatible therapies. Candid’s additional assets, including a CD20xCD3 bispecific and preclinical trispecific TCEs, further strengthen UCB’s next-generation immunology platform. (Link)
  2. Chiesi Group to acquire KalVista Pharmaceuticals (NASD:KALV) for approximately $1.9 billion to strengthen its global rare disease portfolio Chiesi Group has entered into a definitive agreement to acquire KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) for $27.00 per share in cash, representing an equity value of approximately $1.9 billion. The transaction, Chiesi’s largest acquisition to date, adds EKTERLY® (sebetralstat), the first oral, on-demand plasma kallikrein inhibitor for hereditary angioedema (HAE) attacks in patients 12 years and older. Already approved in the U.S., EU, UK, Japan, and other markets with strong commercial uptake ($49 million in 2025 U.S. sales), sebetralstat will bolster Chiesi Global Rare Diseases’ immunology franchise and support the group’s 2030 revenue target of €6 billion. The deal is expected to close in Q3 2026, subject to customary closing conditions including a successful tender offer. (Link)
  3. Atrium Health and WakeMed propose $2 billion strategic combination to expand services and create 3,300 jobs in North Carolina Atrium Health (part of Advocate Health) and Raleigh-based WakeMed have announced a proposed merger that includes a $2 billion investment in Wake County, aimed at expanding access across North Carolina and creating approximately 3,300 new healthcare jobs over five years. The combination would unite North Carolina’s largest health system with the Triangle’s leading community-based provider, enhancing specialty services (cancer, neurosciences, pediatrics), building the state’s largest nonprofit mental health network (>360 inpatient beds), and establishing its largest virtual care platform. Key initiatives include redevelopment of WakeMed’s Raleigh campus, hospital expansions, new Healthplex facilities, and strengthened medical education partnerships with Wake Forest University School of Medicine. The non-binding proposal requires approval from the Wake County Board of Commissioners and is subject to regulatory review. (Link)
  4. CareDx (NASD: CDNA) to acquire Naveris for $160 million upfront plus up to $100 million in milestones to enter viral-mediated cancer MRD surveillance CareDx, Inc. has entered into a definitive agreement to acquire Naveris, a commercial-stage precision oncology diagnostics company specializing in blood-based molecular residual disease (MRD) monitoring for HPV-driven cancers. The transaction includes $160 million in upfront cash consideration and up to an additional $100 million contingent on revenue milestones. Naveris’ flagship NavDx® test, based on proprietary Tumor Tissue Modified Viral (TTMV®) DNA technology, is Medicare-reimbursed and addresses a $4.5 billion total addressable market in head and neck, anal, and other viral-mediated cancers. The company generated approximately $34 million in unaudited 2025 revenue (with Q1 2026 revenue of ~$12 million at 65% gross margin) and has performed over 130,000 commercial tests to date. The acquisition extends CareDx’s precision medicine strategy from transplant diagnostics into specialty oncology while remaining neutral to 2026 Adjusted EBITDA guidance. The deal is expected to close in Q3 2026. (Link)
  5. CareMetx expands its patient access platform through the strategic acquisition of U.S.-based patient services and TheraCom free goods pharmacy operations from Cencora, Inc. (NYSE: COR) CareMetx has successfully completed the acquisition of Cencora’s (COR) U.S. Hub consulting services and its TheraCom pharmacy business to create a more robust technology-enabled services platform. This transaction integrates Cencora’s extensive staffing and pharmacy infrastructure with CareMetx’s AI-driven workflow automation. The deal positions CareMetx to serve over 155 pharmaceutical brands, focusing on reducing treatment barriers and improving patient access to specialty medications. Cencora will transition into a preferred partner role, ensuring a seamless transition for existing clients while leveraging CareMetx’s specialized digital solutions to enhance patient journeys across the healthcare ecosystem. (Link)
  6. Odyssey Therapeutics targets up to $810 million valuation in Nasdaq IPO for autoimmune and inflammatory disease pipeline Odyssey Therapeutics has filed to raise up to $238.3 million in its U.S. initial public offering by offering 13.2 million shares priced between $16 and $18 each, targeting a valuation of up to $809.9 million. The Boston-based biopharmaceutical company is developing precision therapies for autoimmune and inflammatory diseases, with lead candidate OD-001 in a mid-stage (Phase 2) trial for ulcerative colitis. Odyssey plans to list on Nasdaq under the ticker “ODTX,” with J.P. Morgan, TD Cowen, and Cantor serving as lead underwriters. The IPO comes amid a strong resurgence in biotech listings and would provide capital to advance its clinical pipeline in high-unmet-need immune-mediated indications. (Link)
  7. Infinite Epigenetics acquires Tally Health a longevity company co-founded by Dr. David Sinclair, seeded by L Catterton, to build a vertically integrated epigenetic testing platform Infinite Epigenetics has completed the acquisition of Tally Health, marking a major consolidation in the longevity and biological age testing market. The deal combines Tally Health’s consumer-facing brand and TallyAge™ test with Infinite Epigenetics’ scientific infrastructure and DNA methylation datasets. Tally Health will operate as a standalone consumer brand within the Infinite Epigenetics ecosystem, gaining access to advanced diagnostic tools from the TruDiagnostic arm. The acquisition is intended to accelerate the development of personalized interventions for aging and shift the healthcare focus toward proactive longevity. L Catterton, an initial investor in Tally, sees the exit as a milestone in the commercialization of biological age metrics. (Link)
  8. Global clinical research organization Parexel acquires Vitrana to integrate its AI-powered pharmacovigilance platform into Parexel’s comprehensive patient safety and clinical development services Parexel has bolstered its patient safety capabilities through the acquisition of Vitrana, a provider of AI-driven pharmacovigilance technology. The deal allows Parexel to offer an end-to-end safety model that automates data processing for regulatory submissions, reducing the administrative burden on clinical trials. Vitrana’s system-agnostic platform will be integrated into Parexel’s global infrastructure, enabling pharmaceutical clients to achieve greater accuracy in adverse event reporting. This strategic move aims to improve operational efficiency and global compliance while maintaining a focus on high-quality clinical outcomes. Vitrana will operate as a Parexel company, keeping its leadership team to drive continued technological innovation. (Link)
  9. Enterprise oncology platform Azra AI acquires Thynk Health to expand its AI-driven incidental findings and lung cancer screening platform across 500 hospitals Azra AI has acquired Thynk Health to create a unified platform for managing incidental medical findings and cancer screenings. The merger brings together two leaders in the oncology workflow space, serving a combined customer base that includes five of the top ten U.S. health systems. By integrating Thynk Health’s specific expertise in lung cancer screening, Azra AI enhances its ability to identify and track patients from the moment a potential issue is spotted in imaging. The combined entity aims to eliminate patient handoff failures and accelerate the diagnosis of life-threatening conditions. Thynk Health’s leadership will join Azra AI to oversee the expansion of the incidental findings platform. (Link)
  10. Quality data management leader Medisolv, Inc. acquires Health Elements AI to enhance its automated data abstraction and clinical registry reporting capabilities for healthcare organizations Medisolv has acquired Health Elements AI to modernize its clinical data extraction processes using advanced artificial intelligence. The acquisition targets the labor-intensive process of manual chart reviews, aiming to support the 4,000 abstracters using Medisolv’s platform across 1,800 hospitals. By integrating Health Elements’ AI-first software, Medisolv enhances its ability to capture structured data for critical reporting to organizations like the American Heart Association. This move follows Medisolv’s recent acquisition of Lilac Software, reinforcing its commitment to reinventing quality data usage. The combined technology will help healthcare providers transition more effectively to value-based care models by improving data accuracy and reducing staff burden. (Link)
  11. Pinnaql acquires Pharma Resource Group to expand scientific, formulation, and manufacturing advisory capabilities Pinnaql, Inc., a 3 Boomerang Capital portfolio company, has acquired Pharma Resource Group, Inc. (PRG), a provider of analytical sciences, formulation development, scientific writing, manufacturing, and change control advisory services to the pharmaceutical and life sciences industries. This marks Pinnaql’s third tuck-in acquisition in the past 10 months and significantly strengthens its end-to-end offering across the product lifecycle — from laboratory innovation and scale-up to validation, quality systems, regulatory compliance, and commercial readiness. Founded in 2007, PRG brings deep formulation and manufacturing expertise that complements Pinnaql’s existing strengths in engineering, validation, and quality consulting. The deal advances Pinnaql’s strategy to build a scaled, multi-disciplinary advisory platform serving biopharma, medical device, and CDMO clients. (Link)
  12. UConn Health signs letters of intent to acquire Bristol Hospital and Day Kimball Hospital as part of statewide expansion UConn Health has signed letters of intent to acquire Bristol Health (anchored by 154-bed Bristol Hospital) and Day Kimball Hospital (104-bed facility in Putnam), advancing its strategy to build a broader community hospital network across Connecticut. The non-binding agreements aim to close the Bristol transaction by January 2027 and the Day Kimball deal by fall 2026, subject to regulatory approval via the state’s Certificate of Need process. Both independent community hospitals have faced financial challenges, with negative operating margins in recent years, and the affiliations are expected to provide financial stability, expand access to academic medical center expertise, and strengthen UConn Health’s competitive position. The moves follow UConn’s recent acquisition of Waterbury Hospital and align with state-supported efforts to preserve essential healthcare services in the region. (Link)
  13. Nationwide Medical acquires Dynamic Healthcare Services (DHS) to expand home respiratory and durable medical equipment footprint Nationwide Medical, a leading provider of specialized respiratory care and home healthcare solutions, has acquired Dynamic Healthcare Services (DHS), a well-established provider of home respiratory supplies, durable medical equipment (DME), and oxygen therapy products serving Pennsylvania, New Jersey, and surrounding markets. The strategic acquisition strengthens Nationwide Medical’s regional presence and enhances its clinical programming for OSA, COPD, and other chronic respiratory conditions through DHS’s patient-centric model and strong local clinician relationships. This transaction expands access to comprehensive home-based care, including sleep therapy support, patient monitoring programs, and advanced equipment, while integrating DHS’s expertise with Nationwide Medical’s national infrastructure and remote monitoring capabilities. The deal aligns with Nationwide Medical’s growth strategy focused on improving therapy compliance and patient outcomes in the home medical equipment sector. (Link)
  14. The Ensign Group (NASD: ENSG)  acquires real estate and expands operations in Texas with new post-acute care campus The Ensign Group, Inc. has acquired the real estate and operations of a newly constructed 124-bed skilled nursing and rehabilitation facility in Texas, marking its continued expansion in the state. This transaction adds a modern, purpose-built campus to Ensign’s portfolio and brings the total number of operating facilities in Texas to 52. The acquisition aligns with Ensign’s disciplined “pay-for-performance” model and its strategy of entering high-quality, well-located assets in attractive markets. Financial terms were not disclosed. This move further strengthens Ensign’s presence in one of its key growth states and supports its long-term goal of portfolio diversification and operational scale in the post-acute care sector. (Link)
  15. Baystate Health and Trinity Health Of New England sign definitive agreement for integration of Mercy Medical Center Baystate Health has entered into a definitive agreement with Trinity Health Of New England to transition ownership of Mercy Medical Center (a 182-bed acute care hospital in Springfield, MA), its joint venture affiliates, and medical group entities to Baystate Health, subject to regulatory approvals. The transaction will allow Baystate to preserve Mercy’s nonprofit mission and Catholic legacy while providing financial stability and operational support to ensure long-term sustainability of high-quality local care in Western Massachusetts. Trinity Health Of New England will retain ownership of its Brightside for Families and Children services as well as continuing care operations, including Mercy LIFE, Beaven Kelly Home, and Saint Luke’s Home. The move addresses Mercy’s ongoing financial pressures from reimbursement challenges, outpatient shifts, and staffing shortages, strengthening regional access and positioning Baystate as a stronger safety-net provider for the Pioneer Valley. (Link)
  16. AI automation firm 1520ai acquires data insights firm Hospice Analytics to combine hospice-native artificial intelligence with established market utilization datasets. 1520ai has finalized the acquisition of Hospice Analytics, a firm with 20 years of experience in hospice data analysis. The merger unites 1520ai’s predictive modeling with Hospice Analytics’ deep market trends and utilization data to create a new platform focused on regulatory compliance and clinical quality. 1520ai, which has minority backing from simPAL Solutions, plans to use the acquisition to provide hospice providers with real-time answers to operational and financial questions. Hospice Analytics will maintain its branding and its partnership with the National Hospice Locator. (Link)
  17. Superior Health Holdings a Renovus Capital Partners portfolio company, acquires Chant Healthcare to expand its home health and hospice services into the Oklahoma market Superior Health Holdings has expanded into Oklahoma through the acquisition of Chant Healthcare, which operates as Compassion Homecare and Sans Bois Hospice. Backed by Renovus Capital Partners, Superior intends to leverage Chant’s strong presence in 11 Oklahoma counties and its large dual-eligible Medicaid patient base. The acquisition provides a strategic foothold for further expansion into the Oklahoma City and Tulsa markets. Chant Healthcare’s leadership will remain in place to manage local operations while utilizing Superior’s broader administrative and clinical infrastructure. This transaction marks Superior’s entry into its second state, following its established presence in Arkansas, and focuses on scaling rural healthcare delivery through specialized hospice services. (Link)
  18. The Medical University of South Carolina and Revival Healthcare Capital establish a five-year strategic innovation partnership to fund and scale next-generation medical technology solutions The Medical University of South Carolina (MUSC) has entered into a five-year partnership with private equity firm Revival Healthcare Capital to accelerate the commercialization of medical device innovations. Under the agreement, MUSC will provide clinical expertise and validation support for Revival’s portfolio companies, while Revival will provide the capital and operational leadership necessary to scale MUSC-originated technologies. This collaboration is designed to bridge the gap between academic research and commercial medical solutions. The partnership focuses on identifying unmet clinical needs and deploying high-impact medical devices into the healthcare market. Both organizations aim to create a repeatable model for innovation that improves patient outcomes through targeted investment and clinical rigor. (Link)

Venture Deals and Other

  1. DTC health platform Musely secures $360 million in non-dilutive capital from General Catalyst to accelerate customer acquisition for its dermatology and menopause care lines Musely has secured a $360 million capital commitment from General Catalyst through a non-dilutive financing structure. This arrangement allows Musely to fund aggressive marketing and customer acquisition efforts without giving up equity in the company. The funding will primarily support Musely’s core prescription skincare business and its recent expansion into the menopause care market. By utilizing non-dilutive capital, Musely maintains control over its operations while leveraging General Catalyst’s resources to scale its digital platform. The deal highlights a growing trend of high-growth, profitable direct-to-consumer health companies choosing creative financing over traditional venture rounds to fuel expansion. Musely plans to use the funds to reach millions of new patients globally. (Link)
  2. Bio-inspired BCI startup Axoft secures $55 million in Series A funding led by C.P. Group Innovation, with participation from Hillhouse Investment and Gaorong Ventures Axoft has raised $55 million in an oversubscribed Series A round to advance its implantable brain-computer interface (BCI) technology. The round, led by C.P. Group Innovation, included participation from Hillhouse, Gaorong, and the Stanford President’s Venture Fund, bringing Axoft’s total funding to over $60 million. Axoft is developing bio-inspired, soft implants that aim to provide long-term stability for neural communication without damaging brain tissue. The funding will support the expansion of global clinical trials, including the company’s first-in-human studies. This investment underscores the high demand for scalable BCI solutions that can treat neurological disorders. Axoft intends to use the capital to navigate regulatory approvals and scale its manufacturing capabilities. (Link)
  3. Truentity Health secures $35 million in oversubscribed Series A funding led by Evidenced VC, with participation from K-Street Capital, Cofounders Capital, and Tweener Fund. Truentity Health has closed a $35 million Series A round to scale its pharmacy-led clinical care model, which enables community pharmacies to provide chronic disease management services. The investment was led by Evidenced VC and saw participation from regional investors like Cofounders Capital and Tweener Fund. Truentity provides an AI platform that supports pharmacies in delivering reimbursable services such as remote patient monitoring and medication therapy management. The capital will be used to expand the company’s network into new state markets throughout 2026. By turning local pharmacies into clinical hubs, Truentity aims to improve healthcare access in rural areas and provide pharmacies with new, sustainable revenue streams. (Link)
  4. Prescription infrastructure startup Photon secures $16 million in Series A funding led by Healthier Capital, with participation from Notation, Flare Capital, and Evidenced Photon has closed a $16 million Series A funding round to modernize the digital prescription experience for patients and providers. The round was led by Healthier Capital and included participation from Flare Capital and Notation, bringing Photon’s total capital raised to over $25 million. Photon provides an API-driven infrastructure that allows patients to see real-time prescription pricing and stock availability at retail pharmacies. The new funds will support the expansion of Photon’s engineering team and the growth of its commercial partnerships with health systems and digital health brands. By simplifying the prescription routing process, Photon aims to reduce the estimated 20-30% of prescriptions that are currently abandoned by patients. (Link)
  5. AI pathology developer Techcyte bags $15 million in funding led by Van Tuyl Companies, with participation from strategic investors Zoetis Inc. (NYSE: ZTS) and Mayo Clinic. Techcyte has raised $15 million to scale its AI-powered digital pathology platform and drive the company toward profitability. The financing round was led by Van Tuyl Companies and saw continued support from Zoetis (ZTS) and Mayo Clinic. As part of the partnership, Techcyte will leverage Mayo Clinic’s massive dataset of 17 million pathology slides to further train its diagnostic algorithms. The Techcyte Fusion platform is designed to unify human, veterinary, and environmental pathology workflows into a single digital interface. The investment will be used to expand Techcyte’s global footprint and address the critical shortage of laboratory professionals by automating routine and complex diagnostic tasks. (Link)
  6. UnityAI launches its StaffOps platform for outpatient care following an $8.5 million Series A funding round led by Third Prime, with participation from Nashville Capital Network. UnityAI has introduced its AI-powered staffing and operations platform, StaffOps, following an $8.5 million Series A round led by Third Prime. The funding, which included participation from Whistler Capital Partners and Max Ventures, supports the company’s mission to optimize the outpatient healthcare workforce. StaffOps uses agentic AI to handle patient interactions and coordinate clinical tasks, currently managing over 300,000 interactions monthly. UnityAI has already partnered with large groups like Tennessee Oncology to improve clinical throughput and patient access. The new capital will be used to expand UnityAI’s go-to-market team and enhance its EHR integration capabilities, ensuring AI-driven tasks are safe, traceable, and highly efficient for medical staff. (Link)
  7. Specialty clinic automation startup TriFetch raises $1.9 million in pre-seed funding led by Nexus Venture Partners with participation from high-profile angel investors TriFetch has emerged from stealth with $1.9 million in pre-seed capital to develop AI automation tools specifically for independent medical practices. Nexus Venture Partners led the round, which also featured investment from notable angels affiliated with Google and Hippocratic AI. TriFetch’s platform acts as an automation layer that manages administrative tasks like patient scheduling, referral processing, and prior authorizations. Unlike traditional EHRs, TriFetch integrates with existing workflows to reduce the daily “paperwork” burden on clinicians. The funding will be used to build out the core product and expand its reach to more specialty clinics across the U.S., focusing on improving clinic profitability and reducing staff burnout. (Link)
  8. Depth Health raises $1 million in seed funding led by Green Harvest Capital Industries (GHC Industries) to scale its AI-driven hospital throughput optimization platform Depth Health has secured $1 million in seed financing to advance its Augmented Surveillance Intelligence (ASI) platform, which optimizes hospital patient flow and bed management. The funding round was led by Green Harvest Capital Industries, whose CEO, Ankit Patel, will join Depth Health’s Board of Directors. The capital will be used to enhance Depth Health’s explainable AI models, which provide real-time recommendations for patient placement and discharge. By joining the GHC Industries portfolio, Depth Health gains access to a broader ecosystem of clinical intelligence technologies. The investment aims to help hospitals reduce throughput bottlenecks and improve financial performance through data-backed operational efficiency. (Link)
  9. Virchu Sciences secures first institutional funding round to advance AI-powered oncology drug discovery platform Virchu Sciences has closed its first institutional investment round led by the Ohio Innovation Fund, with participation from JobsOhio Ventures and Rev1 Ventures. The Columbus, Ohio-based company operates at the intersection of AI, pharma, biotech, and academic research, developing multimodal AI solutions to accelerate drug discovery, advance treatment identification, and enable precision oncology testing. The new capital will support expansion of its data engineering and AI team, enhancement of its Data Discovery and Delivery Platform, and go-to-market efforts targeting academic institutions and commercial partners. The round underscores strong Ohio ecosystem support for AI-enabled life sciences innovation. (Link) (Link)